



Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012–2018

Paulina Koszalka^{a,b}, Danielle Tilmanis^a, Merryn Roe^a, Dhanasekaran Vijaykrishna^{a,b,c},
Aeron C. Hurt^{a,d,*}

^a WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia

^b Biomedicine Discovery Institute & Department of Microbiology, Monash University, Victoria 3800, Australia

^c Program of Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

^d University of Melbourne, Department of Microbiology and Immunology, Parkville, VIC 3010, Australia

ARTICLE INFO

Keywords:

Baloxavir marboxil
Influenza
Susceptibility
Resistance
Antiviral activity

ABSTRACT

Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to monitor for susceptibility post-BXM use, a cell culture-based focus reduction assay was developed to determine the susceptibility of 286 circulating seasonal influenza viruses, A(H1N1)pdm09, A(H3N2), B (Yamagata/Victoria) lineage viruses, including neuraminidase inhibitor (NAI) resistant viruses, to Baloxavir Acid (BXA), the active metabolic form of BXM. BXA was effective against all influenza subtypes tested with mean EC₅₀ values (minimum-maximum) of 0.7 ± 0.5 nM (0.1–2.1 nM), 1.2 ± 0.6 nM (0.1–2.4), 7.2 ± 3.5 nM (0.7–14.8), and 5.8 ± 4.5 nM (1.8–15.5) obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses, respectively. Using reverse genetics, amino acid substitutions known to alter BXA susceptibility were introduced into the PA protein resulting in EC₅₀ fold change increases that ranged from 2 to 65. Our study demonstrates that currently circulating viruses are susceptible to BXA and that the newly developed focus reduction assay is well suited to susceptibility monitoring in reference laboratories.

1. Introduction

Despite increased vaccination rates in many parts of the world, influenza continues to cause high levels of morbidity and mortality in high-risk groups (Thompson et al., 2009), particularly when influenza seasons are dominated by A(H3N2) viruses (Sullivan et al., 2017). Influenza antivirals are available for the short-term prophylaxis of individuals to prevent influenza infection, but their primary use has been to treat severely ill patients, many of whom are hospitalised. Two classes of influenza antivirals have been licensed for many years, the M2 ion channel inhibitors and neuraminidase inhibitors (NAIs). Clinical use of the M2 ion channel inhibitors, amantadine and rimantadine, is limited as close to 100% of circulating influenza A viruses contain an amino acid (AA) substitution at residue 31 of the M2 protein (S31N) that confers resistance to these compounds (Dong et al., 2015). Four NAIs are licensed in different parts of the world, of which oseltamivir is the most widely available and commonly used. Oseltamivir resistance

has become widespread amongst certain groups of viruses in different periods of time (e.g. seasonal H1N1 between 2007 and 2009 (Hauge et al., 2009; Matsuzaki et al., 2010)), but for the last seven years the frequency of viruses that circulate with reduced NAI susceptibility has remained at less than 5% (Lackenby et al., 2018). The licensure of alternative antivirals, especially those with different modes of action to NAIs, is likely to be of benefit if oseltamivir resistant viruses emerge. In addition, combination therapy may be a strategy to improve clinical effectiveness compared to NAI monotherapy (de Mello et al., 2018).

Baloxavir marboxil (S-033188, BXM) is an influenza polymerase inhibitor that was licensed for the treatment of uncomplicated influenza in Japan and the US in 2018 (Noshi et al., 2016). BXM is a prodrug that is hydrolysed by the enzyme arylacetamide deacetylase to the active form baloxavir acid (S-033447, BXA) (Kawaguchi et al., 2018). BXA is a small molecule inhibitor of the highly conserved cap dependent endonuclease (PA_N) in the PA protein of influenza A and B viruses (Noshi et al., 2018). Inhibition of the PA_N disrupts endonuclease function and

* Corresponding author. WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

E-mail address: Aeron.Hurt@influenzacentre.org (A.C. Hurt).

<https://doi.org/10.1016/j.antiviral.2019.02.007>

Received 30 November 2018; Received in revised form 12 February 2019; Accepted 12 February 2019

Available online 13 February 2019

0166-3542/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

as a consequence the cap-snatching mechanism of the influenza polymerase (Noshi et al., 2018). Treatment of uncomplicated influenza with BXM as a single oral dose was shown in a Phase III clinical trial to reduce influenza symptom duration by 26.5 h compared to placebo, a similar reduction time achieved with oseltamivir (Hayden et al., 2018). However, 24 h post-drug administration the reduction in viral load was twice as large in BXM treated patients compared to oseltamivir treated patients (Hayden et al., 2018).

In post-treatment samples obtained from phase II and III BXM clinical trials, A(H3N2) and A(H1N1)pdm09 viruses with reduced BXA susceptibility were detected and shown to carry AA substitutions at position 38 of the PA_N including I38T, I38M and I38F (Omoto et al., 2018). In the phase II clinical trial (which involved predominantly A(H1N1)pdm09 viruses) an I38 variant emerged in 4 of 182 patients (2.2%), while the phase III study (which involved predominantly A(H3N2) viruses) showed a frequency of an I38 variant in 36 of 370 (9.7%) of BXM recipients (Hayden et al., 2018). The highest frequency of viruses with reduced BXM susceptibility has been reported from a paediatric study, where 18 of 77 (23.4%) of patients had treatment-emerged PA_N/I38 variants (Omoto et al., 2018). The transmissibility of the PA_N/I38 variants between patients in the absence of drug treatment is currently unknown, but *in vitro* studies suggest that these viruses have reduced replication compared with equivalent wildtype strains (Noshi et al., 2018).

Given the frequency of viruses detected post BXM treatment with reduced BXA susceptibility, and potentially the large use of the drug in clinical practice in coming years, it is important to conduct surveillance of circulating strains for BXM susceptibility. This study aimed to develop a high-throughput and reproducible phenotypic assay for surveillance purposes to determine the BXA susceptibility of recently circulating influenza viruses in the Asia-Pacific, thereby proving baseline susceptibility data for which prospective samples can be compared to in the future.

2. Materials and methods

2.1. Antiviral compounds, cells and viruses

20 mM stocks of Baloxavir acid (S-033447; BXA) (kindly provided by Shionogi & Co., Ltd.) were prepared in dimethyl sulfoxide (DMSO) (Sigma Aldrich, USA), filtered with a 0.2 µm surfactant-free cellulose acetate (SFCA) filter (ThermoFisher, USA) and stored in aliquots at –20 °C.

COS-7 African green monkey kidney cells (ATCC, CRL-1651), HEK-293T (ATCC, CRL11268), Madin-Darby canine kidney (MDCK)-TMPRSS2 cells (kindly provided by Dr. Jesse Bloom (Böttcher et al., 2009)) and MDCK-SIAT cells (MDCK cells that overexpress α2,6-linked sialic acids, kindly provided by Dr M. Matrosovich (Matrosovich et al., 2003)), were cultured at 37 °C in a 5% CO₂ gassed incubator in Dulbecco's Modified Eagle Medium (DMEM) (SAFC Biosciences, US). DMEM growth media (DMEM GM) used for the culture of COS-7, HEK-293T and MDCK-TMPRSS2 cell lines was supplemented with: 10% foetal bovine serum (Bovogen Biologicals, Australia), 1x GlutaMAX (Gibco, USA), 1x MEM non-essential amino acid solution (Gibco, USA), 0.06% sodium bicarbonate (Gibco, USA), 20 µM HEPES (Gibco, USA) and 100 U/mL penicillin-streptomycin solution (Gibco, USA). Growth media for MDCK-SIAT cells (DMEM GM SIAT) was supplemented as described for DMEM GM with the addition of 1 mg/mL Geneticin (Gibco, USA).

The influenza viruses used in this study were submitted through the WHO Global Influenza Surveillance and Response System (GISRS) to the WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia. Viruses tested were collected during 2013–2018 from Australia (n = 158), Singapore (n = 58), Malaysia (n = 34), Cambodia (n = 19), Thailand (n = 7), Sri Lanka (n = 3), New Zealand (n = 3), New Caledonia (n = 2) and Fiji (n = 2). All viruses

grown for assay purposes were propagated in MDCK-SIAT cells, using a DMEM maintenance media (DMEM MM) supplemented as DMEM GM, with the addition of 4 µg/mL TPCK-treated trypsin (Worthington, USA) but without foetal bovine serum.

2.2. Site directed mutagenesis and the generation of recombinant viruses

The reverse genetics plasmid pHW2000 (kindly provided by Richard Webby) containing each of the eight gene segments of A/Perth/261/2009 (A(H1N1)pdm09), A/Perth/16/2009 (A(H3N2)) or B/Yamanashi/166/98 virus (B/Yamagata lineage) were utilised for reverse genetics. The Gene Art® Site-Directed Mutagenesis Kit (Life Technologies, USA) and relevant primer pairs were used for site-directed mutagenesis to introduce AA substitutions within the PA gene of each virus. Sanger sequencing was used to confirm AA changes in each plasmid. To generate recombinant viruses an eight-plasmid reverse genetics method adapted from Hoffman et al. was used (Matrosovich et al., 2003). Alterations to the methods include, HEK-293T and MDCK-TMPRSS2 were seeded at an 8:1 ratio with a total of 5×10^5 cells and COS-7 and MDCK-TMPRSS2 at a 3:1 ratio with a total of 3×10^5 cells, for influenza A and influenza B virus experiments, respectively. Gene-Juice® Transfection reagent (Merck Millipore, USA) was used for transfection. MDCK-TMPRSS2 were infected 72 h post-transfection using 1 mL of supernatant from the co-culture. Virus growth was determined using a haemagglutination assay in 1% (v/v) turkey red blood cells and the PA protein sequence was confirmed using Sanger sequencing.

2.3. BXA cytotoxicity assay

The cytotoxicity of BXA was measured to identify non-toxic drug concentrations suitable for use *in vitro*. The inner wells of 96 well plates (Corning, USA) were seeded with MDCK-SIAT cells at a concentration of 2.5×10^5 cells/mL (100 µl/well) and incubated overnight at 37 °C in a 5% CO₂ gassed incubator. The BXA concentration range of 50 µM–0.4 µM was obtained from a two-fold serial dilution of BXA in DMSO (Sigma Aldrich, US) and further diluted in the final MM supplemented with 2 µg/mL TPCK-trypsin overlay. One well was left free of BXA as a negative control. Treated cells were incubated at 35 °C in a 5% CO₂ gassed incubator for 24, 48 and 72 h. Cell viability was determined using the CellTiter-Glo® Luminescent Cell Viability Assay as per manufacturer's instructions (Promega, USA) and luminescence was measured using a FLUOstar Optima luminometer (BMG Labtech, Germany). The BXA concentration that reduces cell viability by 50% compared to the cell only control (CC₅₀) was calculated using non-linear regression analysis (GraphPad Prism, USA).

2.4. Virus titration

Virus titration is required to select a suitable virus dilution for the focus reduction assay (FRA). MDCK-SIAT cells were seeded in the inside wells of 96 well plates (Corning, USA) at a concentration of 2.5×10^5 cells/mL (100 µl/well) and incubated overnight at 37 °C in a 5% CO₂ gassed incubator. The experiment was only continued if the cell monolayer was 100% confluent the following day. MDCK-SIAT cells were infected and immunostained with previously described methods (Tilmanis et al., 2017). Briefly, nine half-log dilutions of viruses to be tested in the FRA were prepared in MM. MDCK-SIAT cell monolayers were removed of DMEM GM SIAT and washed once with PBS. 50 µl of each virus dilution was added to the appropriate wells on each plate with the tenth well mock-infected with MM to serve as a cell-only control. The plates were incubated at 35 °C in a 5% CO₂ gassed incubator for 90 min. The virus inoculum was then removed, cells washed once with PBS and overlaid with 100 µl of infection media (IM). IM contained equal parts 3.2% carboxymethyl cellulose (CMC) (1.6% final) (Sigma Aldrich, US) and 2x MEM (1x final) (Sigma Aldrich, USA) and

was supplemented with 2 µg/mL trypsin. The 2x MEM was supplemented with 20 µM HEPES (Gibco, USA), 100 U/mL Penicillin-Streptomycin (Gibco, USA), 0.06% Sodium Bicarbonate (Gibco, USA). Plates were incubated at 35 °C in a 5% CO₂ gassed incubator for 24 h. Following the incubation period, the cells were fixed with 10% formalin (Sigma Aldrich, US) and permeabilised with 0.5% Triton X-100 (Sigma Aldrich, US). Plates were washed three times in wash buffer (0.05% Tween20 (Sigma-Aldrich, US) in PBS) and incubated for one hour with mouse anti-influenza monoclonal antibody against influenza A virus nucleoprotein (Millipore, USA, Cat#MAB8251) or influenza B virus nucleoprotein (Millipore, USA, Cat#MAB8661), diluted 1: 10,000 in 2% skim milk. Plates were then washed and incubated for one hour with goat anti-mouse IgG-horse radish peroxidase (Biorad, US) secondary antibody, diluted 1:1000 in 2% skim milk. Plates were again washed and then incubated for ten minutes in the dark with TrueBlue™ Peroxidase Substrate (KPL, US) and plates were then washed three times with distilled water, the water was then removed and plates allowed to dry. Focus forming units (FFU) were quantified using the Immunospot BioSpot 5.1.36 (CenturyLink Inc, US).

2.5. BXA focus reduction assay

The concentration of BXA required for a 50% reduction in FFU (EC₅₀) was used to determine susceptibility of influenza viruses to BXA. MDCK-SIATs were seeded and infected as described in section 2.4, however, virus was diluted such that there was 1000–2000 FFU/well, as previously determined by virus titration. Cell monolayers were washed with PBS and eight wells were overlaid with 4-fold serial dilutions of BXA (200–0.01 nM) in 100 µl IM. IM only was added to virus and cell control wells. Plates were incubated and immunostained as described in Section 2.4. Each virus was tested in duplicate wells, the foci were determined as an average of duplicate wells as described above. The EC₅₀ was only calculated if the FFU count was between 500 and 2500 FFU in the virus control well. Using the mean FFU, the percentage inhibition of FFU was calculated with use of the following formula:

$$\text{Percent inhibition} = \left(100 - \frac{X - CC}{VC - CC}\right) \times 100$$

where,

CC = FFU in cell control wells (no virus, no drug)

VC = FFU in virus control wells (virus, no drug).

X = Mean FFU

Using the percent inhibition, the EC₅₀ for BXA of each virus was determined using non-linear regression analysis (GraphPad Prism, USA).

2.6. Yield reduction assay

The yield reduction assay is an alternative method to determine influenza virus BXA susceptibility and was utilised to confirm the data from the FRA. MDCK-SIAT cells were seeded in 96 well plates as described in section 2.4. Test viruses were inoculated quadruplicate in 96 well plates with a MOI of 0.01 TCID₅₀/per well and the viruses were then adsorbed for 1 h at 35 °C. The virus inoculum was then removed, the wells were washed once with PBS and eight wells were overlaid with 4-fold serial dilutions of BXA (200–0.01 nM) in 100 µL MM, with a ninth well as a virus only control and tenth well as a cell only control. Following 24 h the quadruplicate virus samples were pooled and a TCID₅₀ was carried out as previously described (Hurt et al., 2010). The EC₅₀ was derived as described in section 2.5, with FFU substituted with a TCID₅₀ titre.

2.7. Statistical analysis

The Linear regression analysis and unpaired student's t-tests were performed using GraphPad Prism (USA) where p-values < 0.05 were considered statistically significant. To evaluate assay reproducibility, FRA was performed with replicate (n = 48) wells of positive and negative controls (± virus) on a 96-well plate and Z factors were calculated using the equation outlined in (Zhang et al., 1999).

3. Results

3.1. Cytotoxicity of BXA

To determine the maximum working drug concentration for use in the *in vitro* assays, a CellTiterGlo assay was used to measure cell viability in the presence of increasing concentrations of BXA in MDCK-SIAT cells at 24, 48 and 72 h. The MDCK-SIAT cell cytotoxicity (CC₅₀, the 50% reduction of cell cytotoxicity compared to a cell only control) of BXA was 34.1 ± 1.9 µM, 10.1 ± 2.1 µM and 7.8 ± 0.9 µM at 24, 48 and 72 h, respectively.

3.2. Reproducibility of BXA focus reduction assay

Several reproducibility factors were tested to ensure the FRA method was suitable for use as a robust, high throughput screening assay. Z scores were determined at 18, 24 and 30-h post-infection times for three viruses, A/Perth/169/2017 [A(H1N1)pdm09], A/Victoria/189/2017 [A(H3N2)] and B/Sydney/42/2016 [B/Victoria lineage]. The closer a Z score is to the value 1, the more reproducible an assay. For all influenza viruses the exclusion of the outside wells increased the Z-score by 10–30% and therefore was used for subsequent assays. For a 24-h infection time, the Z score was 0.62, 0.73 and 0.69 for A(H1N1) pdm09, A(H3N2) and influenza B test viruses, respectively. For influenza B, the Z score was similar for all infection times (0.58–0.69). In addition to these assays, two control viruses, A/Perth/16/2009 and A/Perth/16/2009-PA/I38M (reduced BXA susceptibility), were tested in n = 12 assays in biological replicates in distinct assays. The minimum and maximum EC₅₀ values and the coefficients of variation were 0.13–1.19 nM (80%) and 6.06–12.49 nM (45%), respectively. The EC₅₀ values obtained in each experimental repeat are shown in Fig. 1. The EC₅₀ values obtained from the yield reduction and FRA were found to be highly comparable for the viruses tested (Table 1). Compared with the respective wildtype virus, the PA_N/I38T variant had a 62-fold increase in the FRA and a 73-fold increase in the yield reduction assay (Table 1).




Fig. 1. Control influenza virus EC₅₀ values for 24-h FRA used to measure BXA susceptibility. Data was derived from 12 independent experiments, A/Perth/16/2009 had a mean ± standard deviation EC₅₀ value of 0.5 ± 0.4 nM and the RG-A/Perth/16/2009-PA/I38M virus had an EC₅₀ of 8.5 ± 3.8 nM.

Table 1
Comparison of EC₅₀ values obtained from the yield reduction assay and focus reduction assay.

Virus Designation	Subtype/Lineage	BXA EC ₅₀ (nM)	
		Yield Reduction Assay	Focus Reduction Assay
RG-A/Perth/261/2009	A(H1N1)pdm09	0.3 ± 0.1	0.6 ± 0.5
RG-A/Perth/261/2009-PA _N /I38T	A(H1N1)pdm09	22.1 ± 9.3	37 ± 18.2
RG-A/Perth/261/2009-PA _N /I38M	A(H1N1)pdm09	2.1 ± 1.7	13.3 ± 7.3
A/Victoria/189/2017	A(H3N2)	0.6 ± 0.14	0.91 ± 0.32
B/Christchurch/558/2015	B/Victoria	1.7 ± 0.8	1.2 ± 0.2
B/Sydney/46/2017	B/Yamagata	4.1 ± 3.1	1.3 ± 0.8
B/South Australia/2/2015	B/Yamagata	2 ± 0.8	1.9 ± 0.8

Mean EC₅₀ values and standard deviations are based on a minimum of three independent experiments.




Fig. 2. BXA Susceptibility of seasonal influenza viruses circulating in the Asia Pacific region between 2012 and 2018. Influenza A(H1N1)pdm09 (n = 89), A(H3N2) (n = 88) and B(Victoria Lineage) (n = 53) and B(Yamagata Lineage) (n = 56) were tested in a 24 h FRA in MDCK-SIAT cells. The EC₅₀ was determined using the percentage inhibition of FFU compared to a no-drug but infected virus control well. The mean ± SD EC₅₀ values for A(H1N1)pdm09, A(H3N2), B/Victoria lineage and B/Yamagata lineage viruses are 0.7 ± 0.5 nM, 1.2 ± 0.6 nM, 7.2 ± 3.5 nM and 5.8 ± 4.5 nM, respectively, and are grouped based on virus subtype/lineage and the year of circulation. Based on a student's T test the mean EC₅₀ of all influenza B viruses was significantly higher than that of influenza A viruses (P < 0.0001).

3.3. Susceptibility of circulating influenza viruses to BXA

BXA EC₅₀ values were obtained for influenza viruses circulating in the Asia-Pacific region between the years 2012 and 2018 (Fig. 2). The mean BXA EC₅₀ of A(H1N1)pdm09 viruses (n = 89) was 0.7 ± 0.5 nM, with maximum and minimum values of 0.1 and 2.1 nM, while n = 88 A(H3N2) viruses had a mean EC₅₀ of 1.2 ± 0.6 nM with minimum and maximum values of 0.1 and 2.4 nM. The mean EC₅₀ value of A(H3N2) viruses were significantly greater than that of A(H1N1)pdm09 viruses (P < 0.0001) based on an unpaired student's T test. B/Victoria lineage viruses (n = 53) had a mean EC₅₀ of 7.2 ± 3.5 nM, with minimum and maximum values of 0.7 and 14.8 nM, while B/Yamagata lineage viruses (N = 56) had a mean value of 5.8 ± 4.5 nM and the minimum and maximum values of 1.8 nM and 15.5 nM, respectively. Based on a student's T test there was no significant difference between the mean of influenza B viruses from the two lineages. Taken together the mean EC₅₀ of all influenza A viruses (1.0 ± 0.6 nM) was approximately 6-fold lower than that of influenza B viruses (6.6 ± 4.1 nM). This difference was statistically significant (P < 0.0001) based on an unpaired student's T test.

3.4. Susceptibility of NAI resistant viruses to BXA

Eleven viruses with neuraminidase AA substitutions that confer reduced susceptibility to oseltamivir, zanamivir, peramivir or laninamivir were screened for susceptibility to BXA using the FRA (Table 2). All viruses tested had EC₅₀ values within the expected range for influenza A (0.1–2.4 nM) and influenza B (0.7–15.5 nM). This data demonstrates

that BXA is active against influenza strains which have reduced susceptibility to NAIs.

3.5. Susceptibility and phenotypic screening of PA_N I38 amino acid substitution to BXA

Substitutions PA_N/I38T/I38M/I38F have been identified in some influenza viruses in BXM clinical trials from patients post-treatment (Omoto et al., 2018), and therefore it is useful to evaluate the BXA susceptibility of viruses with these substitutions in the FRA. The substitutions PA_N/I38T, PA_N/I38M and PA_N/I38F in an A(H1N1)pdm09 viruses had a 65, 23 and 17 fold increases in EC₅₀ compared to respective wild type viruses, respectively, while PA_N/I38M and PA_N/I38F in an A(H3N2) virus both conferred a 16 fold increase in EC₅₀ compared to respective wildtype viruses (Table 3). The PA_N/I38 AA substitutions conferred smaller increases in EC₅₀ in an influenza B virus than they did in the influenza A strains, 5-fold for PA_N/I38T and 2 fold for PA_N/I38M (Table 3). Of the three AA substitutions, PA_N/I38T resulted in the greatest BXA EC₅₀. RG-A/Perth/16/2009-PA_N/I38T and RG-B/Yamanashi/166/98-PA_N/I38F were not able to be rescued by reverse genetics.

4. Discussion

This study aimed to establish a robust and reproducible assay to determine the susceptibility of influenza viruses circulating in the past seven years to the PA_N inhibitor drug BXA. In addition, we investigated the impact of substitutions at position I38 of the PA_N in contemporary A(H1N1)pdm09, A(H3N2) and influenza B viruses on BXA susceptibility to confirm the ability of the assay to detect such variants. Using the FRA method, BXA was shown to be active against all 286 influenza viruses tested that had circulated in the Asia-Pacific from 2012 to 2018. The mean EC₅₀ values obtained in this study for each type/subtype of influenza virus were similar to those described in other studies (Noshi et al., 2016; Takashita et al., 2018; Gubareva et al., 2019).

When comparing the BXA EC₅₀ values of influenza A viruses with influenza B viruses, two noteworthy observations can be made. Firstly, mean BXA EC₅₀ values are approximately 6-fold higher for influenza B viruses than for influenza A viruses. BXA forms a “wing” shaped structure that binds to five key AAs (20, 24, 34, 37 and 38) in a V-shaped conformation within the PA_N active site. However, aside from residue I38, which is conserved across both influenza A and B viruses, the other four positions have different residues in influenza A or B viruses (influenza A viruses: A20, Y24, K34 and A37; influenza B viruses: T20, F24, M34, N37 and I38) (Omoto et al., 2018), which is likely to be the reason for the difference in binding and EC₅₀ values. Lower susceptibility in influenza B viruses compared to influenza A viruses is also observed for oseltamivir, where IC₅₀ values for influenza B viruses are 15–20 fold higher than that of influenza A viruses (Farrukee et al., 2015; Escuret et al., 2008). This difference in *in vitro* oseltamivir susceptibility translates into an *in vivo* effect, where

Table 2
Susceptibility of NAI resistant viruses to BXA.

Virus Designation	Type/subtype/lineage	NA Mutation	NAI IC ₅₀ (nM) [Fold Change to Wild Type]				BXA EC ₅₀ (nM)
			Osetamivir	Zanamivir	Peramivir	Laninamivir	
A/Victoria/2500/2016	A(H1N1)pdm09	H275Y	256.8 [642]	0.59 [1]	17.71 [112]	1.6 [3]	1.4 ± 0.1
A/Malaysia/2/2014	A(H1N1)pdm09	I223R	2.86 [19]	19 [1.4]	7 [0.4]	7.6 [0.4]	0.2 ± 0.1
A/Victoria/1031/2010	A(H3N2)	E119V	24 [120]	0.63 [1.6]	0.18 [0.9]	0.78 [1.3]	1.2 ± 0.1
A/Sydney/236/2014	A(H3N2)	Q136K	0.21 [0.57]	9.8 [11]	0.97 [2.9]	2.8 [2.7]	0.1 ± 0.01
B/Sydney/25/2017	B/Vic	I221T	252.3 [10]	16.8 [7]	15.6 [18]	15.3 [6]	1.1 ± 0.6
B/Malaysia/0471/2016	B/Vic	G104E	1539 [87]	3330.4 [120]	16838 [17724]	2536 [701]	1.3 ± 0.2
B/Christchurch/558/2015	B/Vic	H134Y	63.5 [4]	2.3 [1]	72 [76]	1.7 [2]	1.2±0.2
B/Sydney/726/2017	B/Yam	M464T	25.6 [1]	2.2 [1]	8.6 [10]	1.5 [0.5]	1.9±0.9
B/Brisbane/21/2017	B/Yam	I115T	47 [2]	2.7 [1]	7.8 [9]	3.8 [1.5]	4.9 ± 1.1
B/Sydney/46/2017	B/Yam	V131A	21.3 [1]	32.3 [14]	1.1 [1]	3.1 [1]	1.3 ± 0.8
B/South Australia/2/2015	B/Yam	D197N	89.9[7]	6.3 [3]	19.4 [28.8]	7.4 [3]	1.9 ± 0.8

Values shaded in light grey indicate “reduced NAI inhibition” (Influenza A viruses 10–100 fold and influenza B viruses 5–50 fold greater than the median), and dark grey indicate “highly reduced NAI inhibition” (Influenza A viruses >100 fold and influenza B viruses >50 fold above the median). NAI IC₅₀ values based on single experiments and mean BXA EC₅₀ values and standard deviations are based on three independent experiments.

Table 3
BXA susceptibility of reverse genetics derived influenza viruses with I38 PA_N amino acid substitutions.

Virus Designation (Subtype/Lineage)	PA _N Protein AA Substitution	BXA EC ₅₀ (nM) [Fold Change from wild type]
A/Perth/261/2009 (A(H1N1pdm09))	Wild Type	0.6 ± 0.5
	I38T	37 ± 18.2 [65] **
	I38M	13.3 ± 7.3 [23] **
	I38F	9.6 ± 5.3 [17] **
A/Perth/16/2009 (A(H3N2))	Wild Type	0.5 ± 0.4
	I38M	8.5 ± 3.8 [16] ****
	I38F	8.5 ± 3.7 [16] ****
B/Yamanashi/166/98 (B/Yamagata Lineage)	Wild Type	5.3 ± 4.2
	I38T	26.3 ± 18.1 [5] ns
	I38M	9.1 ± 4.1 [2] ns

Mean EC₅₀ values and standard deviations are based on a minimum of six independent experiments. Fold change in EC₅₀ is compared to wild type virus for each corresponding subtype.

Unpaired students T Test was used to compare mean EC₅₀ values of variants to corresponding wild type virus, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns P > 0.05.

numerous studies have reported reduced clinical effect of oseltamivir against influenza B infections compared with influenza A infections (Sugaya et al., 2007; Kawai et al., 2006; Heinonen et al., 2010; Singh et al., 2003). However based on clinical trial data in patients at high-risk of severe influenza, BXM seems to have a comparable clinical effect against both influenza A and B virus infections (Ison et al., 2018). The second observation of note from this study was that the range of BXA EC₅₀ values for influenza B viruses was considerably larger than it was for influenza A viruses, which may be due to greater variation amongst framework residues in the influenza B PA_N than for influenza A viruses, resulting in subtle impacts on drug binding.

The interaction of PA_N/I38 with BXA is present in both influenza A and B viruses and based on BXM clinical trials, this residue appears prone to selection pressure in both virus types. The I38T AA substitution, which confers the largest change in EC₅₀, results in the loss of a methyl group present in wild type viruses. The absence of a methyl group reduces van der Waals interactions between BXM and influenza PA_N. For drug binding, the presence of T38 also requires a rotational

change in the PA_N that is not necessary in wild type viruses (Omoto et al., 2018). Although the substitutions I38M and I38F in A(H1N1)pdm09 and A(H3N2) viruses conferred 16–25 fold increase in EC₅₀, it is important to note that the EC₅₀ values for these viruses range from 8.5 to 13.3 nM, which is not substantially higher than the mean EC₅₀ of wildtype influenza B viruses (6.6 ± 4.1 nM). Therefore understanding how these *in vitro* findings impact clinical effectiveness and which of the I38 variants are likely to result in reduced clinical effectiveness will be important. The median C₂₄ of BXA in clinical trial patients was 59.7 ng/mL (189 nM) (Koshimichi et al., 2018) and therefore at this level it is likely that the drug will still inhibit I38X variants described in this study and those reported elsewhere (Omoto et al., 2018). However, BXA concentrations at 72 h post-treatment decline to a level that is similar to the EC₅₀ levels of I38T variants, suggesting that these variant viruses may not be readily inhibited by the drug at this time point (Koshimichi et al., 2018).

One disadvantage of the FRA is that it may not be suitable for front-line diagnostic laboratories, where molecular-based genotypic assays are more commonly used due to time, equipment and labour constraints. To date, data indicates that PA_N/I38 AA substitutions are expected to be the most common AA substitutions that confer reduced BXA susceptibility. While the I38 residue appears to be a ‘hot-spot’ for AA substitutions under BXA pressure, there are a small number of other substitutions in the PA_N that have also been reported to reduce susceptibility *in vitro* (such as E199G) (Omoto et al., 2018), and it is likely that additional sites will be detected as clinical use of the drug increases.

This study provides information on the baseline susceptibility of a large number of recently circulating influenza viruses across all relevant subtypes and lineages in the Asia-Pacific. It will be important to continue to test circulating viruses for BXM susceptibility as the antiviral continues to be licensed and used more widely to better understand the molecular determinants of BXA susceptibility, the frequency that such viruses occur, and whether they have the capacity to transmit amongst the community in the absence of drug selective pressure.

Acknowledgments

The Melbourne WHO Collaborating Centre for Reference and

Research on Influenza is supported by the Australian Government Department of Health.

DV is supported by contract HHSN272201400006C from the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, USA.

References

- Böttcher, E., et al., 2009. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. *Vaccine* 27 (45), 6324–6329.
- de Mello, C.P.P., et al., 2018. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. *Eur. J. Pharm. Sci.* 111, 443–449.
- Dong, G., et al., 2015. Adamantane-resistant influenza A viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. *PLoS One* 10 (3), e0119115.
- Escuret, V., et al., 2008. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. *J. Clin. Virol.* 41 (1), 25–28.
- Farrukee, R., et al., 2015. Influenza viruses with B/Yamagata-and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. *J. Antimicrob. Chemother.* 70 (7), 2004–2012.
- Gubareva, L.V., et al., 2019. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. *Euro Surveill.* 24 (3), 1800666.
- Hauge, S.H., et al., 2009. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. *Emerg. Infect. Dis.* 15 (2), 155.
- Hayden, F.G., et al., 2018. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *N. Engl. J. Med.* 379 (10), 913–923.
- Heinonen, S., et al., 2010. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. *Clin. Infect. Dis.* 51 (8), 887–894.
- Hurt, A.C., et al., 2010. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. *J. Virol.* 84 (18), 9427–9438.
- Ison, Michael G., M. M., Portsmouth, Simon, Yoshida, Yuki, Shishido, Takao, Hayden, Frederick, Uehara, Takeki, 2018. Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 study). In: IDweek 2018.
- Kawaguchi, N., et al., 2018. Evaluation of drug–drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects. *Clin. Drug Investig.* 38 (11), 1053–1060.
- Kawai, N., et al., 2006. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. *Clin. Infect. Dis.* 43 (4), 439–444.
- Koshimichi, H., et al., 2018. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. *Clin. Drug Investig.* 38 (12), 1189–1196.
- Lackenby, A., et al., 2018. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. *Antivir. Res.* 157, 38–46.
- Matrosovich, M., et al., 2003. Overexpression of the α -2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. *J. Virol.* 77 (15), 8418–8425.
- Matsuzaki, Y., et al., 2010. A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. *Virol. J.* 7 (1), 53.
- Noshi, T., et al., 2016. S-033447/S-033188, a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains. In: *Open Forum Infectious Diseases*. Oxford University Press.
- Noshi, T., et al., 2018. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. *Antivir. Res.* 160, 109–117.
- Omoto, S., et al., 2018. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. *Sci. Rep.* 8 (1), 9633.
- Singh, S., et al., 2003. Clinical benefits with oseltamivir in treating influenza in adult populations. *Clin. Drug Investig.* 23 (9), 561–569.
- Sugaya, N., et al., 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. *Clin. Infect. Dis.* 44 (2), 197–202.
- Sullivan, S.G., et al., 2017. Low interim influenza vaccine effectiveness, Australia. *Euro Surveill.* 22 (43) 1 May to 24 September 2017.
- Takashita, E., et al., 2018. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. *Front. Microbiol.* 9, 3026.
- Thompson, W.W., et al., 2009. Estimates of US influenza-associated deaths made using four different methods. *Influenza Other Respir. Viruses* 3 (1), 37–49.
- Tilmanis, D., et al., 2017. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. *Antivir. Res.* 147, 142–148.
- Zhang, J.-H., Chung, T.D., Oldenburg, K.R., 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen* 4 (2), 67–73.